This company has been acquired
このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
DICE Therapeutics 過去の業績
過去 基準チェック /06
DICE Therapeutics's earnings have been declining at an average annual rate of -51%, while the Pharmaceuticals industry saw earnings growing at 16% annually.
主要情報
-51.0%
収益成長率
48.6%
EPS成長率
| Pharmaceuticals 業界の成長 | 6.0% |
| 収益成長率 | n/a |
| 株主資本利益率 | -20.1% |
| ネット・マージン | n/a |
| 前回の決算情報 | 30 Jun 2023 |
最近の業績更新
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18収支内訳
DICE Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -104 | 32 | 24 |
| 31 Mar 23 | 0 | -91 | 28 | 0 |
| 31 Dec 22 | 0 | -84 | 26 | 0 |
| 30 Sep 22 | 0 | -77 | 23 | 0 |
| 30 Jun 22 | 0 | -74 | 21 | 0 |
| 31 Mar 22 | 1 | -59 | 16 | 0 |
| 31 Dec 21 | 1 | -49 | 12 | 0 |
| 30 Sep 21 | 1 | -40 | 9 | 0 |
| 30 Jun 21 | 2 | -29 | 7 | 0 |
| 31 Mar 21 | 1 | -27 | 5 | 0 |
| 31 Dec 20 | 1 | -24 | 5 | 0 |
| 31 Dec 19 | 6 | -13 | 4 | 0 |
質の高い収益: DICE is currently unprofitable.
利益率の向上: DICE is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: DICE is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.
成長の加速: Unable to compare DICE's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: DICE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-16.4%).
株主資本利益率
高いROE: DICE has a negative Return on Equity (-20.08%), as it is currently unprofitable.